Modulight

Modulight Bio operates in biotechnology and therapeutics, developing an optogenetic approach to neurological disease rather than a broad portfolio of conventional drug candidates. Its stated platform uses gene therapy and the eOPN3 opsin, with light-based control intended to modulate neuronal activity through synaptic mechanisms. The company describes a focus on selectively inhibiting overactive neurons and on conditions associated with abnormal or excessive neuronal activation. That technical focus distinguishes its stated approach within neurology, although the available profile does not provide clinical data, named indications beyond epilepsy-related patent activity, or evidence of commercial deployment. The company’s categories place it alongside biotechnology, medical, health-care, and therapeutics businesses, while its $12 million seed round indicates early-stage financing rather than later-stage commercial scale. Its potential competitive position will depend on demonstrating safety, delivery, precise light control, and therapeutic benefit in relevant neurological conditions.

Modulight Bio’s disclosed trajectory is that of an early-stage therapeutics company moving from platform development toward funded advancement of its optogenetic approach. The company was founded in 2022 and lists one funding round: a $12 million seed financing dated Nov 13, 2025, led by Jibe Ventures and LocalGlobe with nine investors participating. Three patent-related timeline entries from 2024 address pathologic neuronal cells, illumination and brain temperature in optogenetic activation, and treatment of epilepsy. They suggest work on both therapeutic applications and technical implementation, but do not by themselves confirm granted patents or clinical progress. Future trajectory assessment therefore depends on evidence of development progress, validation, and clinical translation that is not yet specified here.